A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous Bisphosphonates
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
uNTx (Corrected by Creatinine) < 50 Nmol/mmol at Week 13
Urinary N-telopeptide (uNTx) corrected by creatinine (uNTx/Cr) < 50 nmol/mmol at week 13.
13 weeks
No
MD
Study Director
Amgen
Canada: Health Canada
20040114
NCT00104650
January 2005
March 2010
Name | Location |
---|